Analysts expect Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) to report earnings per share (EPS) of ($0.17) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aptose Biosciences’ earnings. The lowest EPS estimate is ($0.19) and the highest is ($0.15). Aptose Biosciences posted earnings of ($0.23) per share in the same quarter last year, which indicates a positive year over year growth rate of 26.1%. The firm is scheduled to announce its next quarterly earnings results on Thursday, May 9th.
According to Zacks, analysts expect that Aptose Biosciences will report full year earnings of ($0.72) per share for the current fiscal year, with EPS estimates ranging from ($0.74) to ($0.69). For the next year, analysts expect that the business will post earnings of ($0.83) per share, with EPS estimates ranging from ($0.94) to ($0.72). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Aptose Biosciences.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last released its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01).
APTO opened at $1.98 on Thursday. The firm has a market cap of $77.66 million, a price-to-earnings ratio of -2.30 and a beta of 1.61. Aptose Biosciences has a 52 week low of $1.57 and a 52 week high of $4.55.
In related news, CFO Gregory K. Chow acquired 15,000 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The stock was acquired at an average price of $1.75 per share, with a total value of $26,250.00. Following the acquisition, the chief financial officer now directly owns 122,014 shares in the company, valued at approximately $213,524.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Erich Platzer sold 20,000 shares of the business’s stock in a transaction dated Tuesday, March 19th. The shares were sold at an average price of $2.19, for a total value of $43,800.00. The disclosure for this sale can be found here.
Several hedge funds have recently modified their holdings of the company. Geode Capital Management LLC purchased a new position in shares of Aptose Biosciences in the 4th quarter valued at $33,000. Noven Financial Group Inc. acquired a new stake in shares of Aptose Biosciences in the 4th quarter worth $27,000. Patriot Financial Group Insurance Agency LLC boosted its position in shares of Aptose Biosciences by 11.4% in the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 57,429 shares of the biotechnology company’s stock worth $110,000 after purchasing an additional 5,890 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Aptose Biosciences by 1,130.9% in the 3rd quarter. Renaissance Technologies LLC now owns 183,401 shares of the biotechnology company’s stock worth $477,000 after purchasing an additional 168,501 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Aptose Biosciences in the 3rd quarter worth $125,000. 7.88% of the stock is owned by institutional investors and hedge funds.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Featured Story: Special Dividends
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.